Adipo Medical Technology Co. (AMT), an Osaka venture company, operates an AMED-supported project on the “Development of Multiple Lineage Precursor Cells from Allogeneic Adipose Tissue as a Cellular Medicine for the Treatment of Severe Heart Failure”, under project leadership of Akinobu Matsuyama at Fujita Medical University. Otsuka has announced that it has signed an agreement with AMT on a joint development of this technology including clinical trials.

Otsuka Pharmaceuticals news release, October 30, 2018